Legato Capital Management LLC Buys 476 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Legato Capital Management LLC raised its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 23,178 shares of the medical instruments supplier’s stock after buying an additional 476 shares during the period. Legato Capital Management LLC owned about 0.10% of LeMaitre Vascular worth $2,136,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Townsquare Capital LLC boosted its holdings in LeMaitre Vascular by 38.0% in the third quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock valued at $4,454,000 after acquiring an additional 13,210 shares during the last quarter. Barclays PLC boosted its stake in shares of LeMaitre Vascular by 394.5% in the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock valued at $3,396,000 after purchasing an additional 29,180 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of LeMaitre Vascular by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock worth $17,789,000 after buying an additional 11,395 shares during the period. Creative Planning raised its stake in shares of LeMaitre Vascular by 20.7% during the third quarter. Creative Planning now owns 3,594 shares of the medical instruments supplier’s stock worth $334,000 after buying an additional 617 shares during the last quarter. Finally, Copeland Capital Management LLC lifted its holdings in LeMaitre Vascular by 1.0% in the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock valued at $108,068,000 after buying an additional 11,318 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 10.79% of the stock is owned by insiders.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $96.94 on Wednesday. The company has a market capitalization of $2.18 billion, a P/E ratio of 52.97, a price-to-earnings-growth ratio of 2.19 and a beta of 0.96. The business has a 50-day moving average of $96.43 and a two-hundred day moving average of $93.37. LeMaitre Vascular, Inc. has a 1 year low of $58.66 and a 1 year high of $109.58.

Analysts Set New Price Targets

LMAT has been the subject of a number of analyst reports. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Barrington Research upped their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular currently has an average rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.